FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106256912> ?p ?o ?g. }

• W2106256912 endingPage "59" @default.
• W2106256912 startingPage "51" @default.
• W2106256912 abstract "The antiestrogen tamoxifen is thought to antagonize the effects of estrogens by competing with them for estrogen receptor (ER) binding. However, tarnoxifen can also reverse multidrug resistance, synergize with cisplatin cytotoxicity, and inhibit growth in ER-negative lung cancer cells. In addition to ERs, rat and human target tissues contain a second binding macromolecule termed the type II estrogen binding site (type II EBS). It has been shown that tamoxifen and flavonoids, a widely distributed class of natural substances with a variety of biologic actions, bind to type II EBS and inhibit the growth of several tumor cell types. At present, conflicting data about ERs and an absence of data about type II EBSs exist for lung tumors. We have tested non-small-cell lung carcinoma cell lines and primary tumor cells for the presence of ERs and type II EBSs and have evaluated the effects of tamoxifen and quercetin (pentahydroxyflavone) on the growth of these cells. Using a whole-cell assay and nuclear and cytosolic radiobinding experiments with [3H]estradiol as tracer, we have found that SK-LU1, SW900, ChaGo-K-1, H441, H661, and A549 cells, as well as primary tumors, bind estrogen specifically. This binding results mainly from the presence of a large number of type II EBSs, whereas ERs are absent or present at low concentrations. Type II EBSs bound tamoxifen and quercetin with similar affinity. Cell counts and a thymidine incorporation assay showed that both compounds inhibit cell growth in a concentration-dependent manner at concentrations ranging from 10 nM to 1 microM. Neither ipriflavone, an isoflavone, nor rutin, the 3-rhamnosylglucoside of quercetin, bound type II EBSs or inhibited cell growth. These findings suggest that tamoxifen and quercetin could regulate lung cancer cell growth through a binding interaction with type II EBSs. This mechanism could also be active in vivo, in that we have observed that nuclear and cytosolic type II EBSs were present in all primary lung cancers tested (n = 12), and that tamoxifen and quercetin were effective in inhibiting in vitro bromodeoxyuridine (BrdU) incorporation and proliferation-cell nuclear antigen expression by neoplastic cells in these cancers." @default.
• W2106256912 created "2016-06-24" @default.
• W2106256912 creator A5021131686 @default.
• W2106256912 creator A5037735176 @default.
• W2106256912 creator A5039375531 @default.
• W2106256912 creator A5062113610 @default.
• W2106256912 creator A5081406568 @default.
• W2106256912 creator A5081901402 @default.
• W2106256912 creator A5085952059 @default.
• W2106256912 creator A5086419286 @default.
• W2106256912 date "1997-07-01" @default.
• W2106256912 modified "2023-10-17" @default.
• W2106256912 title "Interaction with Type II Estrogen Binding Sites and Antiproliferative Activity of Tamoxifen and Quercetin in Human Non-Small-Cell Lung Cancer" @default.
• W2106256912 cites W1906197854 @default.
• W2106256912 cites W1908715206 @default.
• W2106256912 cites W1971191564 @default.
• W2106256912 cites W1982518867 @default.
• W2106256912 cites W1983317797 @default.
• W2106256912 cites W1992307364 @default.
• W2106256912 cites W1996853388 @default.
• W2106256912 cites W2019067920 @default.
• W2106256912 cites W2023117579 @default.
• W2106256912 cites W2026947550 @default.
• W2106256912 cites W2029651131 @default.
• W2106256912 cites W2031635845 @default.
• W2106256912 cites W2032336626 @default.
• W2106256912 cites W2036085643 @default.
• W2106256912 cites W2047892202 @default.
• W2106256912 cites W2059153388 @default.
• W2106256912 cites W2060145371 @default.
• W2106256912 cites W2060834852 @default.
• W2106256912 cites W2064859641 @default.
• W2106256912 cites W2073865988 @default.
• W2106256912 cites W2079457273 @default.
• W2106256912 cites W2081023575 @default.
• W2106256912 cites W2082295228 @default.
• W2106256912 cites W2085277836 @default.
• W2106256912 cites W2088557860 @default.
• W2106256912 cites W2091305449 @default.
• W2106256912 cites W2097149924 @default.
• W2106256912 cites W2109508583 @default.
• W2106256912 cites W2126698050 @default.
• W2106256912 cites W2353852039 @default.
• W2106256912 cites W4297928495 @default.
• W2106256912 doi "https://doi.org/10.1165/ajrcmb.17.1.2728" @default.
• W2106256912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9224209" @default.
• W2106256912 hasPublicationYear "1997" @default.
• W2106256912 type Work @default.
• W2106256912 sameAs 2106256912 @default.
• W2106256912 citedByCount "94" @default.
• W2106256912 countsByYear W21062569122012 @default.
• W2106256912 countsByYear W21062569122013 @default.
• W2106256912 countsByYear W21062569122014 @default.
• W2106256912 countsByYear W21062569122015 @default.
• W2106256912 countsByYear W21062569122016 @default.
• W2106256912 countsByYear W21062569122017 @default.
• W2106256912 countsByYear W21062569122018 @default.
• W2106256912 countsByYear W21062569122021 @default.
• W2106256912 countsByYear W21062569122022 @default.
• W2106256912 countsByYear W21062569122023 @default.
• W2106256912 crossrefType "journal-article" @default.
• W2106256912 hasAuthorship W2106256912A5021131686 @default.
• W2106256912 hasAuthorship W2106256912A5037735176 @default.
• W2106256912 hasAuthorship W2106256912A5039375531 @default.
• W2106256912 hasAuthorship W2106256912A5062113610 @default.
• W2106256912 hasAuthorship W2106256912A5081406568 @default.
• W2106256912 hasAuthorship W2106256912A5081901402 @default.
• W2106256912 hasAuthorship W2106256912A5085952059 @default.
• W2106256912 hasAuthorship W2106256912A5086419286 @default.
• W2106256912 hasConcept C109316439 @default.
• W2106256912 hasConcept C121608353 @default.
• W2106256912 hasConcept C134018914 @default.
• W2106256912 hasConcept C1491633281 @default.
• W2106256912 hasConcept C185592680 @default.
• W2106256912 hasConcept C202751555 @default.
• W2106256912 hasConcept C2776067312 @default.
• W2106256912 hasConcept C2777164284 @default.
• W2106256912 hasConcept C2777176818 @default.
• W2106256912 hasConcept C502942594 @default.
• W2106256912 hasConcept C530470458 @default.
• W2106256912 hasConcept C54355233 @default.
• W2106256912 hasConcept C55493867 @default.
• W2106256912 hasConcept C62112901 @default.
• W2106256912 hasConcept C81885089 @default.
• W2106256912 hasConcept C84606932 @default.
• W2106256912 hasConcept C86803240 @default.
• W2106256912 hasConcept C98274493 @default.
• W2106256912 hasConceptScore W2106256912C109316439 @default.
• W2106256912 hasConceptScore W2106256912C121608353 @default.
• W2106256912 hasConceptScore W2106256912C134018914 @default.
• W2106256912 hasConceptScore W2106256912C1491633281 @default.
• W2106256912 hasConceptScore W2106256912C185592680 @default.
• W2106256912 hasConceptScore W2106256912C202751555 @default.
• W2106256912 hasConceptScore W2106256912C2776067312 @default.
• W2106256912 hasConceptScore W2106256912C2777164284 @default.
• W2106256912 hasConceptScore W2106256912C2777176818 @default.
• W2106256912 hasConceptScore W2106256912C502942594 @default.
• W2106256912 hasConceptScore W2106256912C530470458 @default.

• next